Natera Inc is a leading genetic testing company focused on transforming patient care through innovative genetic insights. Its mission is to improve health outcomes by providing comprehensive genetic information that empowers patients and healthcare providers. Natera's strategy revolves around leveraging advanced technology and data analytics to deliver non-invasive prenatal testing, oncology solutions, and organ transplantation compatibility assessments. By integrating cutting-edge science with a commitment to accessibility, Natera Inc aims to enhance the understanding of genetic conditions and support personalized medicine, ultimately driving better healthcare decisions and outcomes for patients worldwide.

NATERA INC

Natera (NTRA) is generating positive momentum as it prepares to report its fourth-quarter 2024 results, which were released on February 25, 2025. With a Zacks Rank of #2 (Buy) and an impressive Earnings ESP of +61.91%, the company is expected to demonstrate significant earnings growth.

Natera Anticipated to Deliver Strong Fourth-Quarter Earnings with 61.91% Earnings ESP and 34.4% Year-Over-Year EPS Growth

Natera is poised for a remarkable fourth-quarter performance, boasting a 61.91% Earnings ESP and a projected 34.4% year-over-year EPS growth. In a medical sector marked by uncertainty, can Natera's strong fundamentals and impressive track record continue to set it apart?